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Abstract
Background: People with opioid use disorder and severe infections may complete their
prolonged courses of outpatient parenteral antimicrobial therapy at a post-acute care facility
due to adherence and safety concerns. We hypothesized that treatment with medications
for opioid use disorder, such as methadone and buprenorphine, would increase antibiotic
completion in these facilities.
Methods: We performed a retrospective cohort study of people with opioid use disorder and
severe infections who were discharged from the University of Maryland Medical Center to a
post-acute care facility to complete intravenous antibiotic therapy. The primary outcome was
completion of outpatient parenteral antimicrobial therapy. We compared the rate of antibiotic
completion between patients prescribed and not prescribed medication for opioid use disorder
at discharge from the acute care hospital.
Results: A total of 161 patient encounters were included; the mean age was 43.4 years and
56% of patients were male. In 48% of the encounters, the patient was homeless and in 68%
they recently injected drugs. The most common infectious syndrome was osteoarticular
(44.1%). Medication for opioid use disorder was prescribed at discharge in 103 of 161
encounters and was newly started in 27 encounters. Similar rates of outpatient parenteral
antimicrobial therapy completion were found in those who received (65/103) and did not
receive (33/58) medication for opioid use disorder at discharge (odds ratio: 1.29; 95%
confidence interval: 0.68–2.54; p = 0.44).
Conclusion: Medication for opioid use disorder prescription at discharge was not associated
with completion of outpatient parenteral antimicrobial therapy in a post-acute care facility.
Our study is limited by possible selection bias and infrequent initiation of medication for opioid
use disorder, which may have minimized the effect on antibiotic completion.
Keywords: injection drug use, medication for opioid use disorder, outpatient parenteral
antimicrobial therapy, substance use disorder
Received: 11 February 2022; revised manuscript accepted: 10 May 2022.

Introduction
People with opioid use disorder (OUD) frequently have complicated bacterial and fungal
infections such as osteomyelitis, infectious arthritis, and endocarditis,1,2 which are often treated
with prolonged courses of intravenous (IV)

antibiotics. Outpatient parenteral antimicrobial
therapy (OPAT) allows patients to receive IV
antibiotics outside the hospital, usually at home
or in a post-acute care facility. People with OUD
often complete OPAT in post-acute care facilities
(such as skilled nursing or subacute rehabilitation
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facilities), instead of at home, due to concerns
that they will not adhere to the antibiotic dosing
schedule or will use the long-term IV access to
inject non-prescribed drugs.3,4 In small studies,
rates of successful completion of OPAT by people with OUD at post-acute care facilities are
often lower than those receiving OPAT at other
locations.5–7
Medications for opioid use disorder (MOUDs),
such as buprenorphine and methadone, are effective for reducing symptoms of opioid withdrawal,
OUD-related mortality, and illicit opioid use.8–10
Despite this benefit, MOUD are underutilized in
acute care hospitals when people who inject drugs
(PWIDs) are receiving care for complicated infections.11 In people with OUD who received IV
antibiotics only in the hospital (did not receive
OPAT), use of MOUD was associated with
higher rates of IV antibiotic completion.12
Whether MOUD use can increase OPAT completion for people with OUD treated at a postacute care facility is poorly understood. One
retrospective study of people with OUD who
completed IV or oral antibiotics at a medical respite facility did not demonstrate an association
between a four-part intervention that included
MOUD initiation and successful antibiotic completion.13 This study was relatively small and did
not report baseline MOUD use or antibiotic completion by discharge MOUD prescription.
We performed a retrospective cohort study, based
on data from an established academic OPAT program, to test the hypothesis that, for people with
OUD, prescription of methadone or buprenorphine at hospital discharge is associated with
higher rates of OPAT completion at a post-acute
care facility.
Methods
Patient encounters were identified through the
OPAT program database at the University of
Maryland School of Medicine. The OPAT program provides coordination of care and management of IV antibiotics by infectious disease (ID)
nurses, an ID pharmacist, and an ID physician;
receives and acts upon laboratory results; and
coordinates in-person or remote follow-up with
an ID physician. All patients in the OPAT program received ID and case management consultation during the acute care hospitalization.
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Consultation by the addiction psychiatry service
during the hospitalization was provided only if
ordered by the clinical team. Patients included in
this study were discharged from two campuses of
the University of Maryland Medical Center
between 1 October 2017 and 31 April 2020.
Patient encounters were included if they were
adults with a diagnosed substance use disorder
(SUD) other than alcohol or nicotine, had a bacterial or fungal infection requiring OPAT and
were managed by the University of Maryland
School of Medicine OPAT program. Patients
were excluded if they did not have a diagnosis of
OUD, had inactive OUD, completed OPAT in a
place other than a skilled nursing facility (e.g. at
home, at residential drug treatment), or did not
have information about MOUD at discharge.
Multiple encounters from the same patient could
be included.
Data abstraction was performed (by PRC)
through analysis of the OPAT database, discrete
variables exported from the medical record, and
independent review of unstructured clinical notes
(including admission notes, discharge notes, progress notes, and the addiction psychiatry and the
ID consultation notes). Data were collected on
age, sex, race, current experience of homelessness, current injection drug use (IDU), SUD
diagnoses, past diagnosis of human immunodeficiency virus (HIV) infection, addiction psychiatry
consultation, infectious syndromes, pathogens,
OPAT antimicrobials, MOUD (buprenorphine
or methadone) prior to acute care hospital admission and at the time of discharge, and outcome of
OPAT treatment. Patients were characterized as
having current IDU based on the assessment of
the clinicians. SUD diagnoses were made by
selection of International Classification of
Diseases-9
(ICD-9)
or
ICD-10
codes
(Supplemental Appendix A) and then confirmed
by chart review. Patients were characterized as
having inactive OUD if there were both (1) no
illicit opioid use noted and/or inferred based on
clinical notes and urine toxicology tests in the
past year and (2) they were on treatment with
MOUD. Patients were classified as prescribed
MOUD prior to hospital admission or at hospital
discharge based on the medication list, clinical
notes, or the discharge instructions. The primary
outcome was OPAT completion, defined as any
of the following: documentation of cure,
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completion of planned therapy, or transition to
suppressive antimicrobial therapy. Secondary
outcomes included readmission within 30 days of
OPAT completion and death.
We hypothesized that prescription of MOUD at
discharge would increase the rate of OPAT completion. We also conducted an analysis to explore
the effect of MOUD prior to admission. We compared baseline and outcome data by t-test for
ratio data and chi-square or Fisher’s exact tests
for nominal data. The odds ratio for the primary
outcome was calculated by the Baptista–Pike
method. Statistical tests were performed using
GraphPad Prism 9 software.
Results
Out of 263 patient encounters that met the inclusion criteria, 102 encounters were subsequently
excluded: 50 for discharge to somewhere besides
a post-acute care facility (1 to acute rehabilitation, 1 to drug rehabilitation, and 48 to home), 37
who had inactive OUD, 13 for missing information on MOUD at discharge, and 2 who did not
have a diagnosis of OUD. This left 161 encounters in the final analysis, representing 124 unique
patients.
The mean age was 43.4 years and 56% of patients
were male (Table 1). In 48% of the encounters,
the patient was experiencing homelessness, and
in 68%, they were currently injecting drugs. In
48% of encounters, patients had used other substances in addition to opioids and in 53% they
were on MOUD prior to admission. Fourteen
percent of the encounters involved patients with a
diagnosis of HIV infection. Males were less likely
to receive MOUD at discharge than females, but
other baseline characteristics were similar. Most
encounters (79%) included a consultation by the
addiction psychiatry service. Infections were primarily osteomyelitis and/or septic arthritis
(44.1%), followed by endocarditis (26.1%). Most
infections involved a single Gram-positive organism (75.2%). Identified pathogens were commonly methicillin-resistant Staphylococcus aureus
(39.8%), methicillin-sensitive Staphylococcus
aureus (26.1%), or Streptococcus species (23.6%).
Most OPAT treatments (90.1%) involved a single antibiotic, which was usually cephalosporin
monotherapy (46.6%) or glycopeptide monotherapy (23.0%).
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OPAT completion occurred in 33 encounters
(57%) in which MOUD was not prescribed at discharge, compared to 65 encounters (63%) in
which MOUD was prescribed on discharge (Table
2; odds ratio: 1.29, 95% confidence interval:
0.68–2.54). This difference was not statistically
significant (p = 0.44). Patients were readmitted
within 30 days of finishing OPAT in 13 encounters (22.4%) with no MOUD at discharge and in
27 encounters (26.2%) with MOUD at discharge
(p = 0.59). No deaths occurred.
Encounters were further analyzed by MOUD use
prior to hospital admission and at discharge
(Figure 1). MOUD use by encounter was categorized as ‘none’ if not used prior to admission or at
discharge, ‘stopped’ if used prior to admission
but not by discharge, ‘continued’ if used both
prior to admission and at discharge, and ‘started’
if not used prior to admission but started by discharge. OPAT completion occurred in 28 of 49
encounters, in which no MOUD was used; 5 of 9
in which MOUD was stopped, 47 of 78 in which
MOUD was continued, and 18 of 27 in which
MOUD was started. OPAT completion was not
associated with MOUD use prior to admission
and at discharge in a multigroup comparison
(p = 0.85); results were similar when comparing
only the MOUD continued and started groups
(p = 0.66).
Discussion
We performed a retrospective cohort study of
people with OUD who were receiving OPAT for
severe infections at post-acute care facilities.
Participants had high rates of IDU, homelessness,
and multiple SUD diagnoses. Discharge to the
post-acute care facility on methadone or
buprenorphine was not associated with OPAT
completion. A secondary analysis of MOUD
prior to admission and at discharge also did not
show an association with OPAT completion.
Readmission was similar in both groups and no
deaths occurred.
Our study found a similar level of overall OPAT
completion (64%) as other studies of similar populations at skilled nursing facilities or SUD treatment facilities (49-73%).6,13–15 Rates of OPAT
completion may be lower in PWID or those experiencing homelessness,16 which was common in
our study.
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Table 1. Cohort characteristics.
Total (n = 161)

No MOUD at
discharge (n = 58)

MOUD at discharge
(n = 103)

P value

43.4

44.6

42.7

0.31

90 (55.9)
71 (44.1)

39 (67.2)
19 (32.8)

51 (49.5)
52 (50.5)

0.03

White
Black
Latinx

111 (68.9)
48 (29.8)
2 (1.2)

40 (69.0)
16 (27.6)
2 (3.4)

71 (68.9)
32 (31.1)
0

1.00a

Homeless

77 (47.8)

27 (46.6)

50 (48.5)

0.81

109 (67.7)

36 (62.1)

73 (70.9)

0.25

77 (47.8)

22 (37.9)

55 (53.4)

0.06

23 (14.3)

8 (13.8)

15 (14.6)

0.89

MOUD treatment prior to admission

85 (52.8)

9 (15.5)

76 (73.8)

<0.0001

Addiction psychiatry consultation

127 (78.9)

41 (70.7)

86 (83.5)

0.06

14 (8.7)
42 (26.1)
14 (8.7)
71 (44.1)
12 (7.5)
8 (5.0)

5 (8.6)
15 (25.9)
5 (8.6)
28 (48.3)
1 (1.7)
4 (6.9)

9 (8.7)
27 (26.2)
9 (8.7)
43 (41.7)
11 (10.7)
4 (3.9)

ND

107 (66.5)
41 (25.5)
13 (8.1)

42 (72.4)
13 (22.4)
3 (5.2)

65 (63.1)
28 (27.2)
10 (9.7)

MRSA
MSSA

64 (39.8)
42 (26.1)

24 (41.4)
14 (24.2)

40 (38.8)
28 (27.2)

0.91

Streptococcus species

38 (23.6)

11 (19.0)

27 (26.2)

0.30

Single antibiotic
Multiple antibiotic

145 (90.1)
16 (9.9)

54 (93.1)
4 (6.9)

91 (88.3)
12 (12.7)

0.42

Penicillin (class) only
Cephalosporin only
Carbapenem only
Glycopeptide only
Lipopeptides only

7 (4.3)
75 (46.6)
7 (4.3)
37 (23.0)
18 (11.2)

3 (5.2)
32 (55.2)
3 (5.2)
9 (15.5)
6 (10.3)

4 (3.9)
43 (41.7)
4 (3.9)
28 (27.2)
12 (11.7)

Demographics
Mean age, years
Sex
Male
Female
Race

Injection drug use
Additional

SUDb

HIV infection
Addiction treatment

Infections
Primary bacteremia
Endocarditis
Non-endocarditis endovascular infection
Osteomyelitis or septic arthritis
SSTI
Other
Pathogens
Gram-positive monomicrobial
 Other (single or multiple Gram-positive,
Gram-negative, and/or fungi)
No pathogen identified

0.41

Antibiotics

ND

HIV: human immunodeficiency virus; MOUD: medication for opioid use disorder; MRSA: methicillin-resistant Staphylococcus aureus; MSSA:
methicillin-sensitive Staphylococcus aureus; ND: comparison not done due to low numbers in some subgroups; OUD: opioid use disorder; SSTI:
skin and soft tissue infection; SUD: substance use disorder.
aComparison between White and (Black + Latinx) due to low numbers of Latinx.
bIn addition to OUD, excluding nicotine and alcohol.
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Table 2. Outcomes by MOUD at discharge.
No MOUD at
discharge (n = 58)

MOUD at discharge
(n = 103)

OR (95% confidence
interval)

P value

Antibiotic completion

33 (56.9)

65 (63.1)

1.29 (0.68 – 2.54)

0.44

Readmission within
30 days

13 (22.4)

27 (26.2)

1.230 (0.57 – 2.57)

0.59

Death

0

0

MOUD: medication for opioid use disorder; OR: odds ratio.

People with SUD who require OPAT may be
treated at home, at a post-acute care facility, or at
other locations, including residential SUD facilities. Multiple factors may determine the location
for OPAT, and it is difficult to compare non-randomized outcomes among patients in different
locations. Multiple studies have demonstrated
that home OPAT can be effective in people with
OUD or IDU. Vazirian et al.14 found similar
OPAT outcomes for a small number of PWID
and matched controls. Price et al.5 reported 100%
completion of home OPAT in a highly selected
cohort of PWID. D’Couto et al.6 found higher
OPAT completion at home compared to a postacute care facility in people with SUD (81% vs.
64%), and a small randomized study of home
OPAT or in-hospital IV antibiotics by Fanucchi
et al.17 reported 100% antibiotic completion in
both groups, but less drug use in the home OPAT
group. These studies support the hypothesis that
home OPAT may be the most supportive environment for select people.
Despite the demonstrated success of OPAT at
home in certain people with SUD, people with
SUD and serious infections are more likely to be
discharged to a post-acute care facility.18 They may
be more medically complex, may require physical
or occupational therapy, or may not have a suitable
private home for complicated treatments, such as
OPAT. In addition, some people requiring OPAT
may be discharged to a facility because they are
unjustly and illegally excluded from home OPAT
due to their substance use.19 Given the frequency
that people with OUD and serious infections are
treated in post-acute care facilities, approaches to
improve OPAT completion are critical.
Many groups have reported innovative strategies
to improve OPAT care for people who use drugs,
with mixed success. Attempts to coordinate
journals.sagepub.com/home/tai

OPAT at residential SUD treatment facilities
have been met with low uptake by patients.20,21
One program reported significantly lower antibiotic completement rates for PWID with infective
endocarditis treated at a SUD treatment facility
(46%) compared to a historical control group
treated in the hospital (74%), although with similar readmission and mortality outcomes.22
Improving prescription of MOUD during hospitalizations for severe infections may reduce early
patient-directed discharge23 and post-discharge
mortality,24 although many studies have reported
difficulty improving the rate of MOUD use even
with dedicated programs.25,26
Beieler et al.13 performed a small but innovative
study of four different interventions (ID consultation, addiction consultation, case management,
and MOUD at discharge) in people with OUD
experiencing homelessness who were treated with
mostly (86%) IV antibiotics at a residential SUD
treatment facility. The investigators found that
use of all four interventions was associated with
improved clinical cure of infection and retention
in addiction treatment. However, neither the
four-intervention combination nor MOUD alone
were associated with increased antibiotic completion. In fact, none of the individual interventions,
except case management, improved antibiotic
completion, despite rates of MOUD uptake (50%
of encounters with new MOUD start) that were
much higher than in our study. In comparison,
our larger study featured universal case management consultation and reported higher rates of
overall antibiotic completion. The study by
Beieler et al. and this study suggest that improvement of antibiotic completion requires multiple
complex interventions.
Our study is limited by infrequent initiation of
MOUD, which may have minimized the effect of
5
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Figure 1. Antibiotic outcome events by MOUD use prior to admission and at
discharge.
P value by chi-square of all groups = 0.85.

MOUD on antibiotic completion. MOUD initiation and titration are limited by the current regulatory environment. Under current US Drug
Enforcement Administration (DEA) regulations,
methadone cannot be administered for a patient
in a post-acute care facility unless the patient is
already enrolled in an outpatient methadone treatment program. In addition, regulations from the
Substance Abuse and Mental Health Services
Administration limit the starting dose of methadone and may discourage up-titration to effective
doses in acute hospital settings.27 Clinical considerations also limit the rate of dose increases, which
may prohibit the prescription of an effective dose
by the time of hospital discharge. Different regulations restrict buprenorphine use. Outpatient
buprenorphine prescribing is limited to providers
who have a special DEA certification. Outpatient
buprenorphine prescribers may not be available to
patients admitted to a post-acute care facility.
Our retrospective study is also subject to selection
bias between the MOUD groups and due to
exclusion of patients who completed antibiotic
therapy in the hospital. Selection bias may explain
the less-frequent MOUD prescription at discharge for male patients (Table 1). There are also
possible unmeasured confounders, including a
risk that those not prescribed MOUD had lesssevere OUD or less-severe infections and were
therefore more likely to complete antibiotics than
those prescribed MOUD. There are also limits to
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the accuracy of data gathered from the clinical
record, especially characterization of SUD diagnoses and current IDU. We excluded people with
inactive OUD based on clinical and laboratory
assessments, since MOUD may be less likely to
benefit them, but this may have incorrectly
excluded some people with ongoing use that was
unknown to the clinical team. Use of ICD codes
to select the cohort may miss those with incomplete documentation and may erroneously select
patients who use prescribed opioids in the absence
of an SUD. We were also unable to measure continuation of MOUD at post-acute care facilities;
it is possible those who managed to continue
MOUD would have better outcomes. Readmission
or deaths may not have been captured in the
available records. Our findings are from one
urban academic medical center, which limits
generalizability.
The use of MOUD in appropriate patients with
serious infections is only one of many elements that
may improve care. New treatment paradigms of
oral or long-acting IV antibiotics can allow effective
treatment without the issues related to prolonged
IV access, including safety concerns, and possible
requirement for treatment within a facility.28
Prolonged antibiotic treatment of people with
OUD requires careful coordination to continue the
treatment of OUD during care transitions. These
efforts may be aided by changes to the regulatory
framework for MOUD. Intensive and collaborative
clinical care and coordination by dedicated, expert
teams, in the style of tumor boards, can ameliorate
some of the challenges of the fragmented health
and social support systems.29
Improving antibiotic treatment for people with
SUD and severe infections is critical. Solutions
to deliver effective and dignified treatment of
infections in people with SUD will likely
require complex, multimodal approaches, and
will need to be tailored to individual patient
circumstances.
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